<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36537785</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-0241</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of gastroenterology</Title><ISOAbbreviation>Am J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort-Results of an International Multicenter Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>1058</StartPage><EndPage>1068</EndPage><MedlinePgn>1058-1068</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14309/ajg.0000000000002124</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Consumption of green kiwifruit is known to relieve constipation. Previous studies have also reported improvements in gastrointestinal (GI) comfort. We investigated the effect of consuming green kiwifruit on GI function and comfort.</AbstractText><AbstractText Label="METHODS">Participants included healthy controls (n = 63), patients with functional constipation (FC, n = 60), and patients with constipation-predominant irritable bowel syndrome (IBS-C, n = 61) randomly assigned to consume 2 green kiwifruits or psyllium (7.5 g) per day for 4 weeks, followed by a 4-week washout, and then the other treatment for 4 weeks. The primary outcome was the number of complete spontaneous bowel movements (CSBM) per week. Secondary outcomes included GI comfort which was measured using the GI symptom rating scale, a validated instrument. Data (intent-to-treat) were analyzed as difference from baseline using repeated measures analysis of variance suitable for AB/BA crossover design.</AbstractText><AbstractText Label="RESULTS">Consumption of green kiwifruit was associated with a clinically relevant increase of &#x2265; 1.5 CSBM per week (FC; 1.53, P &lt; 0.0001, IBS-C; 1.73, P = 0.0003) and significantly improved measures of GI comfort (GI symptom rating scale total score) in constipated participants (FC, P &lt; 0.0001; IBS-C, P &lt; 0.0001). No significant adverse events were observed.</AbstractText><AbstractText Label="DISCUSSION">This study provides original evidence that the consumption of a fresh whole fruit has demonstrated clinically relevant increases in CSBM and improved measures of GI comfort in constipated populations. Green kiwifruits are a suitable dietary treatment for relief of constipation and associated GI comfort.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gearry</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukudo</LastName><ForeName>Shin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbara</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn-Sherlock</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>BKS Consulting Limited, Hamilton, Waikato, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansell</LastName><ForeName>Juliet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zespri International Limited, Tauranga, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blatchford</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8927-964</Identifier><AffiliationInfo><Affiliation>Zespri International Limited, Tauranga, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eady</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The New Zealand Institute for Plant and Food Research Limited, Palmerston North and Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The New Zealand Institute for Plant and Food Research Limited, Palmerston North and Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butts</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The New Zealand Institute for Plant and Food Research Limited, Palmerston North and Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cremon</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbaro</LastName><ForeName>Maria Raffaella</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagano</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okawa</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muratubaki</LastName><ForeName>Tomohiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Sapporo University of Health Sciences, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuda</LastName><ForeName>Mikiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Nutrition, Tohoku University Hospital, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kano</LastName><ForeName>Michiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanazawa</LastName><ForeName>Motoyori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakaya</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakaya</LastName><ForeName>Kumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drummond</LastName><ForeName>Lynley</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Drummond Food Science Advisory Limited, Killinchy, Canterbury, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02888392</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Gastroenterol</MedlineTA><NlmUniqueID>0421030</NlmUniqueID><ISSNLinking>0002-9270</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2023 May;176(5):JC53. doi: 10.7326/J23-0022.</RefSource><PMID Version="1">37126812</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Guarantor of the article:</b> Richard Gearry, MD, PhD. <b>Specific author contributions:</b> R.G., S.F., and G.B.: principal investigators who oversaw the trial in their respective countries and contributed to writing and review of the manuscript. B.K.S.: conducted the statistical analysis and reviewed the manuscript. J.A.: contributed to trial design and reviewed the manuscript. P.B.: conducted laboratory analysis and reviewed the manuscript. A.W.: and C.B.: involved in running the New Zealand clinical trial and reviewed the manuscript. C.C., M.R.B., and I.P.: involved in running the Italy clinical trial and reviewed the manuscript. Y.O., T.M., T.O., M.F., Y.E., Mi.K., Mo.K., N.K., and K.N.: involved in running the Japan clinical trial and reviewed the manuscript. L.D.: involved with trial design, contributed to writing, and review of the manuscript. <b>Financial support:</b> Zespri International Ltd. was the principal sponsor and reviewed, approved, and funded the study design. The New Zealand study center trial was jointly funded by a grant from the New Zealand government (Contract C11X1312) and the sponsor company, Zespri International Ltd. In Italy and Japan, Zespri International Ltd. was the sole funder for each study center trial. The funder did not contribute to the study design or data analysis. <b>Potential competing interests:</b> J.A. and P.B. are employed by Zespri International who part-funded the study. R.G. and L.D. sit on the Science Advisory Board, have received travel and research grants from Zespri International. SF and GB have received research travel grants from Zespri International.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36537785</ArticleId><ArticleId IdType="pmc">PMC10226473</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000002124</ArticleId><ArticleId IdType="pii">00000434-202306000-00026</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aziz I, Palsson OS, T&#xf6;rnblom H, et al. . The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: A cross-sectional general population study in three countries. Am J Gastroenterol 2018;113(1):86&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">29134969</ArticleId></ArticleIdList></Reference><Reference><Citation>Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology 2019;156(1):254&#x2013;72.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689327</ArticleId><ArticleId IdType="pubmed">30315778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology 2021;160(1):99&#x2013;114.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV. Gastroenterology 2016;150(6):1262&#x2013;79.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144617</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Hasler WL. Rome IV-functional GI disorders: Disorders of gut-brain interaction. Gastroenterology 2016;150(6):1257&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">27147121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharucha AE, Wald A. Chronic constipation. Mayo Clin Proc 2019;94(11):2340&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829047</ArticleId><ArticleId IdType="pubmed">31054770</ArticleId></ArticleIdList></Reference><Reference><Citation>Basilisco G. Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: Analysis of N-of-1 prospective trials in 81 patients. Aliment Pharmacol Ther 2020;51(6):629&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">32048753</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-C, Lin Y-T, Lu Y-T, et al. . Kiwifruit improves bowel function in patients with irritable bowel syndrome with constipation. Asia Pac J Clin Nutr 2010;19(4):451&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21147704</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AOO, Leung G, Tong T, et al. . Increasing dietary fiber intake in terms of kiwifruit improves constipation in Chinese patients. World J Gastroenterol 2007;13(35):4771&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4611199</ArticleId><ArticleId IdType="pubmed">17729399</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunillera O, Almeda J, Mascort JJ, et al. . Improvement of functional constipation with kiwifruit intake in a Mediterranean patient population. An open, non-randomized pilot study. Span J Hum Nutr Diet 2015;19(2):58&#x2013;67.</Citation></Reference><Reference><Citation>Chey SW, Chey WD, Jackson K, et al. . Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in US patients with chronic constipation. Am J Gastroenterol 2021;116(6):1304&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">34074830</ArticleId></ArticleIdList></Reference><Reference><Citation>Rush EC, Patel M, Plank LD, et al. . Kiwifruit promotes laxation in the elderly. Asia Pac J Clin Nutr 2002;11(2):164&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074185</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer SB, Frampton CM, Gearry RB, et al. . Habitual green kiwifruit consumption is associated with a reduction in upper gastrointestinal symptoms&#x2013;a systematic scoping review. Adv Nutr 2022;13(3):846&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9156379</ArticleId><ArticleId IdType="pubmed">35266507</ArticleId></ArticleIdList></Reference><Reference><Citation>Attaluri A, Donahoe R, Valestin J, et al. . Randomised clinical trial: Dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther 2011;33(7):822&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21323688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf W, Park F, Lof J, et al. . Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 2007;9(6):639&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">8824651</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;linas P. Preventing constipation: A review of the laxative potential of food ingredients. Int J Food Sci Technol 2013;48(3):445&#x2013;67.</Citation></Reference><Reference><Citation>Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150(6):1393&#x2013;407.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Andrews CN, Macqueen G, et al. Canadian association of gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). J Can Assoc Gastroenterol 2019;2(1):6&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6507291</ArticleId><ArticleId IdType="pubmed">31294724</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt LJ, Prather CM, Quigley EM, et al. . Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100(Suppl 1):S5&#x2013;S22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16008641</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth GF, Thompson WG, Chey WD, et al. . Functional bowel disorders. Gastroenterology 2006;130(5):1480&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11(2):395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>US. Department of Health and Human Services, Food and Drug Administration (FDA), Centre for Drug Evaluation and Research (CDER). Guidance for Industry: Irritable Bowel Syndrome- Clinical Evaluation of Drugs for Treatment. Silver Spring, MD: US Department of Health and Human Services, FDA, 2012.</Citation></Reference><Reference><Citation>Shin A, Camilleri M, Kolar G, et al. . Systematic review with meta-analysis: Highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39(3):239&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">24308797</ArticleId></ArticleIdList></Reference><Reference><Citation>Svedlund J, Sj&#xf6;din I, Dotevall G. GSRS&#x2014;a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33(2):129&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">3123181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32(9):920&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95(4):999&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">10763950</ArticleId></ArticleIdList></Reference><Reference><Citation>McNair D, Lorr M, Doppleman L. EITS Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service, 1971.</Citation></Reference><Reference><Citation>Dehghan M, Akhtar-Danesh N, McMillan CR, et al. . Is plasma vitamin C an appropriate biomarker of vitamin C intake? A systematic review and meta-analysis. Nutr J 2007;6(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200644</ArticleId><ArticleId IdType="pubmed">17997863</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M, Thorne NK, Ringel Y, et al. Wireless pH-motility capsule for colonic transit: Prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterology Motil 2010;22(8):874&#x2013;82, e233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911492</ArticleId><ArticleId IdType="pubmed">20465593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther 2007;27(2):186&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17973643</ArticleId></ArticleIdList></Reference><Reference><Citation>Metcalf AM, Phillips SF, Zinsmeister AR, et al. . Simplified assessment of segmental colonic transit. Gastroenterology 1987;92(1):40&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">3023168</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. Guideline on multiplicity issues in clinical trials; EMA/CHMP/44762/2017. Committee for Human Medicinal Products (CHMP), Editor. EMA/CHMP/44762/2017 ed. United Kingdom; 2017.</Citation></Reference><Reference><Citation>World Health Organization. Mean BMI (kg/m2) (crude estimate) (last updated 2017-09-27). Body mass index (BMI) among adults. World Health Organisation, 2022.  (https://www.who.int/data/gho/data/indicators/indicator-details/GHO/mean-bmi-(kg-m-)-(crude-estimate).</Citation></Reference><Reference><Citation>Khanna D, Hays RD, Shreiner AB, et al. Responsiveness to change and minimally important differences of the patient-reported outcomes measurement information system gastrointestinal symptoms scales. Dig Dis Sci 2017;62(5):1186&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5532518</ArticleId><ArticleId IdType="pubmed">28251500</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: A Rome foundation working team report. Am J Gastroenterol 2011;106(10):1749&#x2013;59; quiz 60.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747417</ArticleId></ArticleIdList></Reference><Reference><Citation>EFSA Panel on Nutrition Novel Foods and Food Allergens NDA, Hirsch-Ernst KI, Turck D, Castenmiller J, et al. Green kiwifruit (lat. Actinidia deliciosa var. Hayward) and maintenance of normal defecation: Evaluation of a health claim pursuant to article 13(5) of regulation (EC) No 1924/2006. EFSA J 2021;19(6):e06641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193538</ArticleId><ArticleId IdType="pubmed">34136006</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong MYW, Hebbard G, Gibson PR, et al. . Chronic constipation and abdominal pain: Independent or closely interrelated symptoms? J Gastroenterol Hepatol 2020;35(8):1294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">31900961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielefeldt K, Levinthal DJ, Nusrat S. Effective constipation treatment changes more than bowel frequency: A systematic review and meta-analysis. J Neurogastroenterol Motil 2015;22(1):31&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699720</ArticleId><ArticleId IdType="pubmed">26717930</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer SB, Gearry RB, Drummond LN. Putative mechanisms of kiwifruit on maintenance of normal gastrointestinal function. Crit Rev Food Sci Nutr 2017;58(14):2432&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28557573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson-Smith V, Dellschaft N, Ansell J, et al. Mechanisms underlying effects of kiwifruit on intestinal function shown by MRI in healthy volunteers. Aliment Pharmacol Ther 2019;49(6):759&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590324</ArticleId><ArticleId IdType="pubmed">30706488</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2016;150(6):1469&#x2013;80.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">27147123</ArticleId></ArticleIdList></Reference><Reference><Citation>Judkins TC, Dennis-Wall JC, Sims SM, et al. . Stool frequency and form and gastrointestinal symptoms differ by day of the menstrual cycle in healthy adult women taking oral contraceptives: A prospective observational study. BMC Womens Health 2020;20(1):136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325082</ArticleId><ArticleId IdType="pubmed">32600463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: Part 18 of a series on evaluation of scientific publications. Deutsches &#xc4;rzteblatt Int 2012;109(15):276&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345345</ArticleId><ArticleId IdType="pubmed">22567063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>